Biomimetic tumor cell membrane-camouflaged nanomicelles for synergistic chemo-immunotherapy of Triple-negative breast cancer
Triple-negative breast cancer (TNBC) remains a clinical challenge due to its aggressive nature. Conventional chemo-immunotherapy suffers from poor tumor targeting and systemic toxicity, necessitating advanced delivery systems for synergistic drug combinations. This study constructed a biomimetic nan...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-08-01
|
| Series: | Materials Today Bio |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590006425005824 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849682806689497088 |
|---|---|
| author | Xiaoman Xu Yunmei Song Mingli Li Fengxi Liu Huiwen Zhang Jingxia Xu Juwei Gao Yanna Lv Bo Zhang Sanjay Garg |
| author_facet | Xiaoman Xu Yunmei Song Mingli Li Fengxi Liu Huiwen Zhang Jingxia Xu Juwei Gao Yanna Lv Bo Zhang Sanjay Garg |
| author_sort | Xiaoman Xu |
| collection | DOAJ |
| description | Triple-negative breast cancer (TNBC) remains a clinical challenge due to its aggressive nature. Conventional chemo-immunotherapy suffers from poor tumor targeting and systemic toxicity, necessitating advanced delivery systems for synergistic drug combinations. This study constructed a biomimetic nanodrug delivery system by coating nanomicelles with 4T1 tumor cell membranes. This strategy leverages the homologous targeting ability of tumor cell membranes to improve the accumulation of nanomicelles within TNBC tissues. The cytotoxic agent bortezomib (BTZ) and the immune modulator resiquimod (R848) were encapsulated individually and co-administered to investigate the synergistic chemo-immunotherapeutic efficacy in TNBC treatment. The biomimetic nanomicelles exhibited excellent biocompatibility and homologous targeting capacity, significantly enhancing drug delivery efficiency at the tumor site. In vitro studies demonstrated that biomimetic nanomicelles effectively induced tumor cell apoptosis, repolarized tumor-associated macrophages toward the M1 phenotype and promoted dendritic cell maturation. In vivo experiments further confirmed that the biomimetic nanomicelles markedly inhibited tumor growth and metastasis, enhanced antitumor immune responses, and exhibited strong synergy with BTZ to improve overall therapeutic outcomes in TNBC. This dual-action biomimetic nanomicelles delivery platform achieved efficient chemo-immunotherapeutic synergy and represents a promising strategy for targeted treatment of TNBC, with strong potential for clinical translation. |
| format | Article |
| id | doaj-art-b51685027fbb441a8a8cdad729feacbb |
| institution | DOAJ |
| issn | 2590-0064 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Materials Today Bio |
| spelling | doaj-art-b51685027fbb441a8a8cdad729feacbb2025-08-20T03:24:04ZengElsevierMaterials Today Bio2590-00642025-08-013310201210.1016/j.mtbio.2025.102012Biomimetic tumor cell membrane-camouflaged nanomicelles for synergistic chemo-immunotherapy of Triple-negative breast cancerXiaoman Xu0Yunmei Song1Mingli Li2Fengxi Liu3Huiwen Zhang4Jingxia Xu5Juwei Gao6Yanna Lv7Bo Zhang8Sanjay Garg9School of Pharmacy, Shandong Second Medical University, Weifang, 261053, Shandong Province, PR China; School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia, 5000, AustraliaSchool of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia, 5000, AustraliaSchool of Life Science and Engineering, Jining University, Qufu City, 273155, Shandong Province, PR ChinaDepartment of Clinical Pharmacy, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Jinan, 250014, Shandong Province, PR ChinaSchool of Pharmacy, Shandong Second Medical University, Weifang, 261053, Shandong Province, PR ChinaSchool of Pharmacy, Shandong Second Medical University, Weifang, 261053, Shandong Province, PR ChinaSchool of Pharmacy, Shandong Second Medical University, Weifang, 261053, Shandong Province, PR ChinaSchool of Pharmacy, Shandong Second Medical University, Weifang, 261053, Shandong Province, PR China; Corresponding author.School of Pharmacy, Shandong Second Medical University, Weifang, 261053, Shandong Province, PR China; School of Life Science and Engineering, Jining University, Qufu City, 273155, Shandong Province, PR China; Corresponding author. School of Life Science and Engineering, Jining University, Qufu City, 273155, Shandong Province, PR China.School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, South Australia, 5000, AustraliaTriple-negative breast cancer (TNBC) remains a clinical challenge due to its aggressive nature. Conventional chemo-immunotherapy suffers from poor tumor targeting and systemic toxicity, necessitating advanced delivery systems for synergistic drug combinations. This study constructed a biomimetic nanodrug delivery system by coating nanomicelles with 4T1 tumor cell membranes. This strategy leverages the homologous targeting ability of tumor cell membranes to improve the accumulation of nanomicelles within TNBC tissues. The cytotoxic agent bortezomib (BTZ) and the immune modulator resiquimod (R848) were encapsulated individually and co-administered to investigate the synergistic chemo-immunotherapeutic efficacy in TNBC treatment. The biomimetic nanomicelles exhibited excellent biocompatibility and homologous targeting capacity, significantly enhancing drug delivery efficiency at the tumor site. In vitro studies demonstrated that biomimetic nanomicelles effectively induced tumor cell apoptosis, repolarized tumor-associated macrophages toward the M1 phenotype and promoted dendritic cell maturation. In vivo experiments further confirmed that the biomimetic nanomicelles markedly inhibited tumor growth and metastasis, enhanced antitumor immune responses, and exhibited strong synergy with BTZ to improve overall therapeutic outcomes in TNBC. This dual-action biomimetic nanomicelles delivery platform achieved efficient chemo-immunotherapeutic synergy and represents a promising strategy for targeted treatment of TNBC, with strong potential for clinical translation.http://www.sciencedirect.com/science/article/pii/S2590006425005824Biomimetic nanomicellesHomologous targetingChemo-immune combination therapyTriple-negative breast cancer |
| spellingShingle | Xiaoman Xu Yunmei Song Mingli Li Fengxi Liu Huiwen Zhang Jingxia Xu Juwei Gao Yanna Lv Bo Zhang Sanjay Garg Biomimetic tumor cell membrane-camouflaged nanomicelles for synergistic chemo-immunotherapy of Triple-negative breast cancer Materials Today Bio Biomimetic nanomicelles Homologous targeting Chemo-immune combination therapy Triple-negative breast cancer |
| title | Biomimetic tumor cell membrane-camouflaged nanomicelles for synergistic chemo-immunotherapy of Triple-negative breast cancer |
| title_full | Biomimetic tumor cell membrane-camouflaged nanomicelles for synergistic chemo-immunotherapy of Triple-negative breast cancer |
| title_fullStr | Biomimetic tumor cell membrane-camouflaged nanomicelles for synergistic chemo-immunotherapy of Triple-negative breast cancer |
| title_full_unstemmed | Biomimetic tumor cell membrane-camouflaged nanomicelles for synergistic chemo-immunotherapy of Triple-negative breast cancer |
| title_short | Biomimetic tumor cell membrane-camouflaged nanomicelles for synergistic chemo-immunotherapy of Triple-negative breast cancer |
| title_sort | biomimetic tumor cell membrane camouflaged nanomicelles for synergistic chemo immunotherapy of triple negative breast cancer |
| topic | Biomimetic nanomicelles Homologous targeting Chemo-immune combination therapy Triple-negative breast cancer |
| url | http://www.sciencedirect.com/science/article/pii/S2590006425005824 |
| work_keys_str_mv | AT xiaomanxu biomimetictumorcellmembranecamouflagednanomicellesforsynergisticchemoimmunotherapyoftriplenegativebreastcancer AT yunmeisong biomimetictumorcellmembranecamouflagednanomicellesforsynergisticchemoimmunotherapyoftriplenegativebreastcancer AT minglili biomimetictumorcellmembranecamouflagednanomicellesforsynergisticchemoimmunotherapyoftriplenegativebreastcancer AT fengxiliu biomimetictumorcellmembranecamouflagednanomicellesforsynergisticchemoimmunotherapyoftriplenegativebreastcancer AT huiwenzhang biomimetictumorcellmembranecamouflagednanomicellesforsynergisticchemoimmunotherapyoftriplenegativebreastcancer AT jingxiaxu biomimetictumorcellmembranecamouflagednanomicellesforsynergisticchemoimmunotherapyoftriplenegativebreastcancer AT juweigao biomimetictumorcellmembranecamouflagednanomicellesforsynergisticchemoimmunotherapyoftriplenegativebreastcancer AT yannalv biomimetictumorcellmembranecamouflagednanomicellesforsynergisticchemoimmunotherapyoftriplenegativebreastcancer AT bozhang biomimetictumorcellmembranecamouflagednanomicellesforsynergisticchemoimmunotherapyoftriplenegativebreastcancer AT sanjaygarg biomimetictumorcellmembranecamouflagednanomicellesforsynergisticchemoimmunotherapyoftriplenegativebreastcancer |